Nuclear factor-jB (NF-jB) and p53 critically determine cancer development and progression. Defining the cross talk between these transcription factors can expand our knowledge on molecular mechanisms of tumorigenesis. Here, we show that induction of replicational stress activates NF-jB p65 and triggers its interaction with p53 in the nucleus. Experiments with knockout cells show that p65 and p53 are both required for enhanced NF-jB activity during S-phase checkpoint activation involving ataxiatelangiectasia mutated and checkpoint kinase-1. Accordingly, the pro-inflammatory cytokine tumor necrosis factora (TNF-a) also triggers formation of a transcriptionally active complex containing nuclear p65 and p53 on jB response elements. Gene expression analyses revealed that, independent of NF-jB activation in the cytosol, TNFinduced NF-jB-directed gene expression relies on p53. Hence, p53 is unexpectedly necessary for NF-jB-mediated gene expression induced by atypical and classical stimuli. Remarkably, data from gain-and loss-of function approaches argue that anti-apoptotic NF-jB p65 activity is constitutively evoked by a p53 hot-spot mutant frequently found in tumors. Our observations suggest explanations for the outstanding question why p53 mutations rather than p53 deletions arise in tumors of various origins.
Introduction
Homeostasis crucially depends on the regulation of cell proliferation. This is prominently evident in cancer, which is caused by aberrant proliferation due to defective cell-cycle checkpoints. Among transcription factors, the contribution of nuclear factor-kB (NF-kB) and p53 to cancer development and progression is well documented (Hanahan and Weinberg, 2000; Karin, 2006; Finkel et al., 2007) .
Aberrant NF-kB activity is linked to disorders of the immune system, cancer development and resistance against chemotherapy. The NF-kB family consists of p65 (Rel A), Rel B, c-Rel, NF-kB1/p50 and NF-kB2/ p52, which form homo-or heterodimers. Inhibitory factor kB (IkBs; IkBa-e, BCL3, p105 and p100) sequester NF-kB in the cytosol and mask the transcriptional competence of NF-kB. Induction of NF-kB is mediated by the IkB kinase complex by the so-called 'classical' and 'alternative' pathways, which both involve degradation of IkBs (Yilmaz et al., 2003; Perkins, 2007; Wietek and O'Neill, 2007; Renner and Schmitz, 2009 ). In addition, a heterogeneous group of 'atypical' NF-kB activators, for example, UV light or genotoxic stress, result in NF-kB activation characterized by slow kinetics (Janssens and Tschopp, 2006; Scheidereit, 2006; Tergaonkar, 2006) . Low levels of basally active nuclear NF-kB appear to be independent of cytoplasmic NF-kB regulation (Wu and Lozano, 1994; Royds et al., 1998; Kra¨mer et al., 2006) .
In contrast to NF-kB, the transcription factor p53 is a first-line tumor suppressor induced by stimuli endangering genome integrity. The p53 protein activates genes promoting apoptosis, senescence and cell-cycle control. The exact regulation of p53-mediated cell-cycle arrest or apoptosis is complex and depends on the cellular context and specific stress stimuli (Vogelstein et al., 2000; Moll et al., 2005; Vousden and Lane, 2007) . Inactivation of the p53 pathway is observed in most human cancers, with mutations in p53 occurring in at least 50% of all tumors (Soussi and Wiman, 2007) . Interestingly, in addition to the lack of tumor suppressive functions, p53 mutants gain oncogenic activities contributing to carcinogenesis and drug resistance (Moll et al., 2005; Deppert, 2007; Vousden and Lane, 2007) .
Considering the deregulation of NF-kB and p53 pathways in numerous cancers, it is not surprising that an extensive cross talk between both pathways exists at various levels (Perkins, 2007) . For example, NF-kB attenuates p53 protein stability by inducing the E3 ubiquitin ligase MDM2 (Tergaonkar et al., 2002; Kashatus et al., 2006) . Furthermore, the NF-kB2 gene promoter is activated by p53 mutants, and p52 can modulate the promoter activity of p53 target genes (Scian et al., 2005; Schumm et al., 2006) . Moreover, p65 and p53 compete for co-activators, for example, the histone acetyltransferases p300 and CBP (Ravi et al., 1998; Wadgaonkar et al., 1999; Webster and Perkins, 1999; Huang et al., 2007) .
Replicational arrest leads to activation of p53 and NF-kB and can therefore be used as a model to study their cross-signaling (Ansari et al., 2001; Gottifredi et al., 2001; Wu and Miyamoto, 2008) . We now show that p53 is indispensable for enhanced NF-kB p65 transcriptional activity induced by S-phase arrest. Remarkably, p53 also promotes NF-kB functions after induction of classical NF-kB signaling with the cytokine tumor necrosis factor-a (TNF-a). Furthermore, mutant p53 augments tumor-promoting anti-apoptotic activities of NF-kB p65.
Results
Regulation of NF-kB and p53 during S-phase arrest Hydroxyurea (HU) arrests cells in S phase by inhibition of ribonucleotide reductase, the enzyme providing cells with deoxynucleotides for DNA replication. HU is used to treat hematological malignancies and also to inhibit the growth of tumor cells from other entities (Schrell et al., 1996; Bug et al., 2005; Kra¨mer et al., 2008) . We found that a therapeutically achievable dose of HU (Bug et al., 2005) stalled up to 70% of MCF7 cells in S-phase without notable signs of excessive cell death. Therefore, we chose these Caspase-3 null breast cancer cells as a model for signaling induced during replicational arrest (Figure 1a) .
Stalling of replication forks activates both pro-and anti-apoptotic signaling by p53 and NF-kB (Ansari et al., 2001; Gottifredi et al., 2001; Wu and Miyamoto, 2008) . We analyzed whether treatment of MCF7 cells with HU induces NF-kB target genes. Indeed, S-phase arrest enhanced the expression of several genes under control of this transcription factor, BCL-XL, FasL, MnSOD, TRAF1 and Survivin (Figure 1b ). These are, for example, important for signaling, apoptosis, immune functions and the elimination of reactive oxygen species. In contrast to a strong accumulation of p53 in HUtreated cells, the levels of NF-kB p65, p50/p105 and p52/ p100 remained constant under such conditions (Figure 1b and data not shown). Hence, NF-kB target gene activation during S-phase arrest cannot simply be explained by increased NF-kB expression. Analyzing cytosolic and nuclear fractions obtained from MCF7 cells, we found a time-dependent accumulation of NF-kB p65/p50 together with p53 in the nuclei of cells arrested in S phase (Figure 1c) . Hence, nuclear accumulation of p65/p50 and p53 induction correlates with NF-kB target gene expression on DNA replication arrest.
To further verify the induction of NF-kB-dependent gene expression in HU-treated cells, we analyzed lysates of MCF7 cells with avidin-biotin-coupled DNA (ABCD) assay. Increased amounts of NF-kB p65/p50 were recovered with a cognate kB consensus oligonucleotide (Kra¨mer et al., 2006) , but not with a control oligonucleotide. Thus, treatment of MCF7 cells with HU augments the affinity of NF-kB for DNA (Figure 1d ). This finding can explain the enhanced expression of its target genes during S-phase arrest. Of note, a markedly increased amount of p53 specifically associated with p65/p50 on kB DNA after cells had been treated with HU. Direct immunoprecipitations in the absence of exogenously added oligonucleotides confirmed that in response to HU nuclear p65 interacts with p53 in a timedependent manner (Figure 1e ).
These observations show that p53 expression, complex formation of p53 with p65 and NF-kB target gene expression are induced during replicational stress. (Ctl) . Expression of NF-kB-regulated genes, p53, NF-kB members and Tubulin (loading control) was analyzed by western blot analysis. (c) MCF7 cells were treated with HU (1.5 mM) for 6-24 h, or left untreated (0). Expression of NF-kBregulated genes and NF-kB members was analyzed by western blot analysis of cytosolic and nuclear fractions. HDAC1 and Tubulin are markers for the purity of the fractions. (d) Avidin-biotincoupled DNA (ABCD) assay to detect the binding of NF-kB family members and p53 to a kB consensus site. MCF7 cells were treated as stated in (b). Input (IN) represents 10% of whole cell extract used for the assay. The specificity and purity of the assay used were tested by probing for IkB p105, which cannot bind an NF-kB consensus oligonucleotide (FasL m , mutant oligonucleotide from the FAS ligand promoter). (e) MCF7 cells were treated for 0-24 h with 1.5 mM HU. NF-kB p65 was immunoprecipitated from nuclear fractions. Western blot analysis was probed for precipitated p65 and co-bound 53 (pre, precipitation with pre-immune serum; IgG, IgG heavy chain).
Control of activated NF-jB by p53
G Schneider et al
HU induces NF-kB p65
We tested our results from ABCD assays with an additional method. We chose electrophoretic mobility shift assays (EMSAs) using a kB site different from the one for ABCD assays and cell lysates from murine embryonic fibroblasts (MEFs). These experiments revealed that HU also induced an NF-kB complex on this kB consensus sequence. This complex, which was also induced by TNF-a, was supershifted strongly with an antibody specific for p65 (Figure 2a ). To further validate this result, we tested Rel A (p65)-deficient MEFs side by side with wild-type MEFs in both ABCD and EMSA. HU did not induce a detectable complex between kB consensus DNA in Rel A À/À MEFs and p53 was subsequently not recovered ( Figure 2b ). We deduce that p53 is recruited to kB oligonucleotides by p65.
NF-kB proteins can promote anti-apoptotic gene expression and Rel A À/À MEFs are more susceptible to TNF-induced apoptosis (Gapuzan et al., 2005) . We asked whether a lack of Rel A correlates with an increased cytotoxicity in response to HU. Using MTT assays, we noted that Rel A-deficient MEFs were more sensitive toward HU than their wild-type counterparts (Figure 2c) . A recent report (Wu and Miyamoto, 2008) also suggested that NF-kB p65 is a key member during replicational arrest.
It was shown that different isolates of Rel A-deficient MEFs frequently harbor mutated p53 that could generate different reactions of wild-type and such knockout MEFs toward HU (Gapuzan et al., 2005) . Following this publication, we treated wild-type and Rel A-deficient MEFs with the topoisomerase II inhibitor doxorubicin and analyzed cells for p53 and its target gene p21. We observed accumulation of p53 and p21 arguing that p53 is wild-type in both cell lines used (Figure 2d ).
These findings indicate that NF-kB p65 is as a major and functional component in the HU-induced protein/ DNA complex.
NF-kB target gene induction in response to replicational stress requires p53 Next, we evaluated whether p53 is indeed necessary for NF-kB target gene expression during S-phase arrest. We silenced p53 with shRNA and analyzed the expression of the NF-kB target genes FasL and MCL1. Basal levels of these proteins were enhanced in cells with silenced p53 (Figure 3a) , which is consistent with a negative cross-regulation between NF-kB and p53 in unstimulated cells (Hoffman et al., 2002; Kawauchi et al., 2008a, b) . In contrast, products of genes controlled by NF-kB did not accumulate in DNA replication-arrested cells with low p53 levels ( Figure 3a) . Moreover, this dependency on p53 could not be overcome with higher dose of HU ( Figure 3b ). Concordant observations were made for p53-positive and p53-negative mammary epithelial cells (Nayak and Das, 2002) and other matched cells with different p53 background (Szoltysek et al., 2008) . Moreover, HU was reported to activate NF-kB in p53-positive 70Z/3 pre-B cells but not in HEK293 cells (Wu and Miyamoto, 2008) harboring aberrations in the p53 pathway (Lowe and Ruley, 1993) .
To further prove the contribution of p53 to NF-kB activation after HU treatment, we used HCT-116 cells and engineered p53 knockout cells (HCT-116 p53À (Bunz et al., 1998)) . These allowed us to analyze p53-NF-kB cross-signaling in similar genetic backgrounds with wildtype p53 or no p53 at all. Basal expression of several independent NF-kB target genes was enhanced in p53 null cells (Figures 3c-e) . Like in MCF7 cells, p53 was again indispensable for the induction NF-kB target genes in colon cancer cells treated with HU ( Figure 3c ). This effect was time dependent with different NF-kB target genes responding to a various extent and with different kinetics (Figure 3d ). This has similarly been detected in other cellular systems treated with HU (Wu and Miyamoto, 2008) . We additionally asked whether treatment with HU generates pro-apoptotic p53-dependent gene expression. In HCT-116 cells, S-phase Control of activated NF-jB by p53 G Schneider et al checkpoint activation promoted expression of BAX dependent on p53 (Figure 3d ). These data support previous observations (Nayak and Das, 2002) showing that HU does not globally inhibit p53-dependent gene expression.
To exclude indirect mechanisms contributing to the upregulation of NF-kB target genes on HU treatment, we additionally investigated early HU-induced events. As shown in Figure 3e , already after 2 h of HU treatment, we observed upregulation of the NF-kB target genes BCL2 and Survivin in HCT-116 p53 þ cells. These data argue for a direct p53-mediated effect on NF-kB target genes.
To substantiate the contribution of p53 toward the replication stress-dependent induction of NF-kB target genes, we used further model systems. Whereas p53 is induced concomitantly with the NF-kB target genes Survivin and FasL on HU treatment in p53 wild-type RKO colon cancer cells, high expression and a lack of HU-mediated induction was observed in H1299 lung cancer cells harboring a p53 deletion (Szoltysek et al., 2008) (Figure 3f ). Furthermore, replication fork arrest induced expression of p53 and Survivin in wild-type MEFs, but not in p53-null MEFs. Again basal expression of Survivin was increased (Figure 3g ).
We summarize that immediate and delayed NF-kBmediated gene expression in cells with stalled S phase is under control of p53.
NF-kB and p53 are required for replication stress signaling involving ATM and CHK1 To test direct recruitment of p53 to NF-kB target gene promoters, we performed chromatin immunoprecipitation assays in HCT-116 and HCT-116 p53À cells. Indeed, replicational stress induced recruitment of p65 together with p53 to NF-kB target genes. In HCT-116 p53À cells we observed increased basal binding of p65 to the NF-kB promoter investigated, which was even decreased on HU treatment (Figure 4a ). These data are consistent with the basal and HU-induced expression levels of NF-kB target genes in this cellular model. Likewise, a negative impact of p53 toward NF-kB-dependent gene expression under basal conditions was reported by others (Hoffman et al., 2002; Perkins, 2007; Kawauchi et al., 2008a, b) .
We asked if DNA binding is an absolute requirement for HU-induced NF-kB-dependent target gene expression. Caffeic acid phenethyl ester (CAPE) specifically inhibits DNA binding of NF-kB in cancer cells (Natarajan et al., 1996; Gilmore and Herscovitch, 2006; Ha et al., 2009) . Experiments conducted with CAPE revealed that replicational arrest induced NF-kB target genes strictly dependent on the ability of NF-kB to attach to target DNA (Figure 4b ). Consistent with previous reports (Hung et al., 2003; Lee et al., 2003) , we found that CAPE induced p53. Nevertheless, CAPE suppressed expression of the NF-kB target genes Survivin and MnSOD even in the presence of HU. Thus, NF-kB-dependent gene induction in HU-treated cells is only possible when p65 can bind to its target DNA. These findings agree with those shown in Figure 2b .
Recent experiments showed that the DNA-damage modules ataxia-telangiectasia mutated (ATM)/checkpoint kinase-2 (CHK2) and ataxia-telangiectasia and Rad3-related (ATR)/CHK1 are activated by single- Figure 3 p53 controls nuclear factor-kB (NF-kB) target gene expression accentuated by S-phase arrest. (a) MCF7 cells were electroporated with shRNA against p53 or a nonspecific shRNA. At 48 h later, cells were treated with hydroxyurea (HU) (1.5 mM, 24 h) or left untreated (Ctl). Expression of NF-kB-regulated genes, p53, and Tubulin, GAPDH and Actin as three independent loading controls was analyzed by western blot analysis. (b) Same as in a, except that cells were incubated with up to 3 mM HU for 6 h. Western blot analysis was carried out as indicated. (c) HCT-116 cells (p53 þ , wild-type; p53À, p53 knockout) were treated with 1.5 mM HU for 24 h. Expression of NF-kB-regulated genes, p53, NF-kB members and Tubulin was analyzed by western blot analysis. (d) HCT-116 cells (p53 þ /p53À) were treated with HU (1.5 mM, 0-24 h). Expression of p53, the anti-apoptotic NF-kB target genes Survivin and BCL-XL, and the pro-apoptotic p53 target gene BAX were determined by western blot analysis. (e) HCT-116 cells (p53 þ /p53À) were treated with HU (1.5 mM, 2 h). Protein expression analyses were carried out by western blot as specified. (f) RKO and H1299 cells were treated with HU (1 or 1.5 mM, respectively, for 24 h). Expression levels of Survivin, FasL, p53 and Actin were detected by western blot analysis. (g) Wild-type (WT) and p53 À/À murine embryonic fibroblasts (MEFs) were treated with HU (0.5 or 1.5 mM, 16 h). Levels of p53, Survivin and p65 were determined by western blot analysis.
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G Schneider et al stranded DNA exposed at replication forks (Ho et al., 2006; Grallert and Boye, 2008; Wu and Miyamoto, 2008 ). Therefore, we tested if the p53 effects we observed could be explained by different effects on checkpoint kinase signaling. We detected HU-induced phosphorylation of CHK1 ( Figure 4c ) and ATM (Figure 4d ) in p53-positive and p53-negative HCT-116 cells at different treatment time points. Similar results were obtained for p53-deficient and p53-proficient MEFs (data not shown). These results disfavor that a lack of S-phase kinase activation accounts for the lack of NF-kB target gene induction in cells without p53. Consistent with a previous report (Gottifredi et al., 2001) , we noted that ATM phosphorylation not necessarily promotes degradation of the human double minute 2 E3 ubiquitin ligase (Figure 4c ). Other E3s may degrade p53 ATMdependently (Dornan et al., 2006) or alternative mechanisms mediate p53 stabilization during S-phase arrest.
On the basis of these results, we conclude that the p65/p53 complex formed on kB DNA on replicational stress translates into productive NF-kB target gene expression. Formation of this complex still permits p53-mediated signaling.
TNF-a-induced NF-kB target gene expression requires p53
Having assessed the critical function of p53 for NF-kB induction, we determined whether p53 also has an impact on NF-kB induction by the physiological stimulus TNF-a. We treated MCF7 and HCT-116 cells with this pro-inflammatory cytokine and analyzed NF-kB p65/p50 DNA binding with ABCD assays. Independent of p53 expression, NF-kB binding to a cognate oligonucleotide peaked at 20 min after TNF stimulation (Figures 5a and b) . Similar to HU-induced NF-kB activation, we observed a specific recruitment of p53 to the NF-kB consensus oligonucleotide, peaking 10 min after stimulation with TNF-a (Figures 5a and b) . Nuclear p53 is though not necessary for nuclear translocation of NF-kB (Figure 5c ). These findings are in agreement with the well-established model of cytokine-mediated activation of NF-kB signaling in the cytosol.
To investigate whether the TNF-evoked binding of p53 to NF-kB consensus DNA is functionally required for enhanced NF-kB target gene expression, we performed quantitative RT-PCR and western blot analyses. We stimulated HCT-116 and HCT-116 p53À cells with TNF-a and analyzed the expression of NF-kB-regulated genes. We found that TNF-a induced these genes only in p53-positive HCT-116 cells on mRNA and protein levels (Figures 5d and e) . However, there was no induction of p53 expression in cells exposed to 5-50 ng/ml TNF-a (Figure 5e ).
These findings suggest that this cytokine activates nuclear functions of NF-kB dependent on basal p53 expression levels.
TNF-a and HU induce formation of an NF-kB/p53 complex on DNA Immunoprecipitation experiments disclosed that similar to HU, TNF-a induced the formation of a complex between nuclear p65 and p53 (Figure 6a) . Furthermore, EMSAs showed that HU as well as TNF-a induced NFkB complexes that could be supershifted with antibodies specific for p53 in wild-type MEFs (Figure 6b ; compare Figures 2a and b) . To control specificity of the p53 supershift, we used wild-type and p53-deficient MEFs. As shown in Figure 6c , the HU-and TNF-a-evoked NF-kB complex built on NF-kB consensus DNA was not supershifted in p53-deficient MEFs. Again, the HUinduced NF-kB complex was supershifted by p53 antibodies in wild-type MEFs (Figure 6c ). We tested p53À cells were treated with 1.5 mM HU for 24 h or were left as vehicle-treated control. Sheared chromatin of these cells was immunoprecipitated with p65-or p53-specific antibodies, or IgG control antibodies as a negative control. Precipitated DNA or 10% of the chromatin input was amplified with gene-specific primers for the FasL, MnSOD or GAPDH promoters. (b) p53 þ cells were treated with caffeic acid phenethyl ester (CAPE) (12.5 mM; 16.5 h) or/and HU (1.5 mM, 16 h). Expression levels of p53, Survivin, MnSOD and Actin were determined by western blot analysis. The panel also shows a shorter film exposure for detection of Survivin for comparison. (c) Lysates from HCT-116 (p53 þ /p53À) cells treated with HU (1.5 mM; 4 h) were analyzed by western blot analysis for p-CHK1, human double minute 2 (HDM2), and Tubulin (n.sp., nonspecific band). (d) HCT-116 cells (p53 þ /p53À) were treated with HU (1.5 mM, 1-4 h) or etoposide (10 mM, 1 h) as a positive control. Phosphorylation of ATM and Tubulin levels was determined by western blot analysis.
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Similar to that in Figure 2a , we tested for the specificity of this complex with wild-type and Rel A-deficient MEFs proficient for p53 (Figure 2d ). When we added TNF-a for 1-10 h to such cells, we only detected the NF-kB complex in wild-type MEFs (Figure 6e) . Thus, the possibility that a cryptic p53 site within the nucleotide exists can once more be ruled out. Likewise, only wild-type MEFs induced NF-kB-controlled pro-inflammatory genes and a cell adhesion molecule (Figure 6f) .
Hence, halted replication fork signaling and classical activation by TNF-a stimulate p65/p53 complex formation on kB consensus DNA and subsequent gene induction in various cell types.
Mutant p53
R172H activates tumor-promoting NF-kB target gene expression Next, we analyzed whether mutant p53 contributes to NF-kB activity, we established new cellular models with genetically defined p53 backgrounds and the possibility to express p53 from its endogenous promoter. We isolated cell lines from primary pancreatic ductal adenocarcinomas of mice with homozygous deletions of p53 (W22 and 6554 cells) or homozygous expression p53 R172H (5436 cells) (Jonkers et al., 2001; Hingorani et al., 2005; Seidler et al., 2008) . The p53 R172H protein bears a so-called 'hot-spot' mutation corresponding to p53 R175H frequently found in human tumors. When we compared NF-kB-dependent reporter gene expression in W22 and 5436 cells, we detected significantly higher activities of a specifically NF-kB-dependent luciferase reporter in 5436 cells (Figure 7a ). NF-kB target genes regulating signaling and cell survival were consistently more strongly expressed in 5436 cells (Figure 7b) .
Because Survivin reveals the most strikingly divergent expression in W22 and 5436 cells, we compared the activities of a reporter construct containing the Survivin promoter in these cells. Increased expression of Survivin paralleled increased transcriptional activity of the Survivin promoter in 5436 cells positive for p53 R172H . (0) and TNF-a-treated ( þ ; 50 ng/ml; 20 min) HCT-116 cells (p53 þ /À) were analyzed by western blot analysis for the localization of the NF-kB subunits p65 and p50, and of p53.
The western blot analysis also shows a shorter film exposure for detection of p65. (d) Quantitative RT-PCR was used to detect expression of the NF-kB target genes TRAF1 and BCL-XL. HCT-116 cells expressing or lacking p53 (p53 þ /À) were stimulated with TNF-a ( þ ; 50 ng/ml; 4 h). The mRNA levels measured in untreated p53-positive HCT-116 cells were set as 1. Data show a representative experiment and are normalized to 18S RNA. (e) HCT-116 cells (p53 þ /À) were treated with TNF-a ( þ ; 5-50 ng/ml; 4 h). Expression levels of BCL-XL, MnSOD and Tubulin were determined by western blot analysis.
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In contrast, an SP1-dependent UAS-TK reporter was equally active in both cell lines (Figure 7c and data not shown). Western blot and microscopical analyses strengthened this observation and in addition revealed that NF-kB p65 was expressed and localized equally in both cell lines (Figure 7d and data not shown) . Furthermore, the transcriptional repressors HDAC1-4, HDAC7, SIRT1, mSIN3, and the histone acetyltransferase CBP were also expressed at similar levels in W22 and 5436 cells (data not shown). These findings disfavor the possibility that variations in the expression of these factors account for the differential NF-kB transcriptional activities in our models.
Corresponding to the low expression of anti-apoptotic NF-kB target genes in W22 cells, we also observed increased sensitivity of these cells toward HU (Figure 7e ). TNF-a treatment also enforced stronger caspase activation in W22 cells, although Caspase-3 was expressed at the same level as in 5436 cells (Figure 7e ). These data are consistent with a recent report showing that H1299 lung cancer cells overexpressing mutant p53 R175H are less sensitive to TNF-a (Weisz et al., 2007) . These data elucidate that mutant p53 significantly contributes to the productivity of classical NF-kB signaling at the level of gene induction.
Mutant p53
R172H forms a transcriptionally relevant complex with NF-kB on its target DNA Of note, even in unstimulated 5436 cells p53 R172H , which itself cannot bind to DNA, could be co-precipitated with active, nuclear p65 in solution (Figure 8a ). Mutant Figure 6 The hydroxyurea (HU)/tumor necrosis factor (TNF)-inducible nuclear factor-kB (NF-kB) p65 complex contains p53. (a) HCT-116 cells were treated with TNF-a ( þ ; 50 ng/ml; 20 min). Nuclear fractions of these cells were subjected to p65-immunoprecipitation (IP) and detection of p53 and p65 in western blot analysis (IN, 10% of material used for IP). (b) The binding of NF-kB to a kB consensus site was analyzed with electrophoretic mobility shift assay (EMSA). Wild-type murine embryonic fibroblasts (MEFs) were treated with HU (1.5 mM; 24 h) or murine TNF-a (20 ng/ml; 1 h). NF-kB complexes formed under these conditions were supershifted (SS) with p53 antibodies showing the presence of p53 in NF-kB complexes on DNA (pre, pre-immune serum was used as a control). (c) Same as in a, with matched wild-type and p53 À/À MEFs for direct comparison giving affirmation for antibody and complex specificity. (d) Wild-type (WT) and p53 À/À MEFs were treated with HU (1.5 mM, 6 h). Levels of p53 bound to the kB consensus site were assessed by avidin-biotin-coupled DNA (ABCD) assay. (e) Wild-type (WT) and matched p65 À/À MEFs were treated with TNF-a (20 ng/ml; 1-10 h). Levels and specificity of the p65 complex were detected with supershift (SS) and comparison of signals obtained for the two MEF cell lines. (f) Wild-type (WT) and matched p65 À/À MEFs were treated as indicated. Real-time PCRs were carried out for three independent genes (relative induction is in relation to Actin mRNA as an internal reference gene).
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R172H was also recovered with a kB oligonucleotide (Figure 8b ). Binding of p65 was also detected in W22 cells arguing that these pancreatic ductal adenocarcinoma tumor cells have active NF-kB and that p53 R172H potently enhances NF-kB-dependent anti-apoptotic gene expression. Thus, regarding complex formation with p65 and induction of anti-apoptotic gene expression, the p53 R172H mutant behaves as wild-type p53 under conditions of replicational stress and cytokine stimulation.
To show the dependency of Survivin and BCL-XL on NF-kB in 5436 cells, we again used CAPE. As shown in Figure 8c , treatment of 5436 cells with CAPE leads to a distinct decrease of Survivin and BCL-XL expression. To further validate whether the regulation of Survivin depends on p53 R172H and p65 expression, we used RNAi. Similar to the decrease of Survivin in p65 siRNAtransfected 5436 cells, levels of Survivin decreased on attenuation of p53 R172H (Figure 8d ). To independently validate the p53 R172H -dependent expression of Survivin, we reconstituted p53 R172H expression in p53-deficient 6554 cells, which are equally sensitive to HU as W22 cells (Figure 8e ). Compared to parental and vector control 6554 cells, 6554 cells expressing p53 R172H presented increased Survivin levels (Figure 8f ). This finding confirms that p65 and mutant p53 induce expression of Survivin.
Discussion
Cross talk between p53 and p65 is appreciated as an important regulator of tumorigenesis. We used R172H and Survivin (Topro, unspecific DNA dye) . (e) 5436 and W22 cells were treated with hydroxyurea (HU) (1.5 mM, 24 h). Viability of the cells was determined by MTT assay, untreated cells (À) are set as 100% (left). Cells were treated with murine TNF-a for 24 h as indicated. Caspase activation was measured by Caspase-3/7 assay (middle) (*Po0.05). Expression and localization of Caspase-3 (Casp3) was analyzed by cellular fractionation followed by western blot analysis (C, cytosol; N, nucleus) . SIRT1 and Actin serve as markers for the purity of the fractions and equal loading (right).
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biochemical and genetic assays to analyze how wildtype and mutant p53 influence NF-kB signaling. Our analyses rely on several cancer cell models and MEFs, in which p53 and p65 are modulated in highly similar genetic backgrounds. Moreover, we use a newly established cellular system in which a p53 mutant is expressed from its endogenous promoter. We show the novel and unexpected finding that p53 significantly contributes to nuclear NF-kB activity induced during S-phase arrest and remarkably also in response to TNF-a. Furthermore, we show that mutant p53 activates endogenous NF-kB p65-dependent gene expression counteracting apoptosis induced by HU and TNF-a. Our results, summarized in Figure 8g , contribute to a deeper understanding of the cross talk between NF-kB and p53. At first glance, a requirement of p53 for gene expression dependent on the tumor promoter NF-kB contradicts the well-established tumor suppressor function of p53. However, our results reveal a regulatory circuit placing stress-dependent expression of prosurvival NF-kB target genes, such as Survivin, under control of p53. Cells with p53 levels insufficient to promote transcriptional activities of NF-kB are consequently disfavored. Pronounced stress and damage can dynamically switch to a p53-inducible apoptotic program (Zhang et al., 2009 ) ensuring genomic fidelity. Thus, our findings suggest that p53 dictates cell fate decisions not only at the level of cell-cycle arrest and induction of pro-apoptotic genes but also at the level anti-apoptotic gene expression by Rel A/p65. Given that checkpoint proteins have functions in normal S phase (Grallert and Boye, 2008; Levine, 2009) , our conclusions might as well apply for regular S-phase entry.
An additional layer controlling apoptosis on strong induction of the intra-S checkpoint could rely on R172H were decreased with siRNAs against these transcription factors (si Ctl, irrelevant siRNA sequence). Western blot analysis shows efficacy of knock-downs and levels of Survivin and Actin. (e) MTT assays were carried out for W22 p53 À/À , 6554 p53 À/À and 5436 p53 R172H cells left untreated (À) or placed in the presence of 1.5 mM for 24 h ( þ ; *Po0.05). (f) p53 R172H was stably expressed in 6554 cells lacking endogenous p53 (UT, untransduced; RCAS Ctl, empty RCAS vector; RCAS p53 R172H #1/2, independently generated 6554 cell lines reconstituted with p53 R172H ). Western blot analysis shows p53, Survivin and Actin levels. (g) Model for the p53/p65 cross talk. In response to replicational arrest or stimulation with tumor necrosis factor-a (TNF-a), p53 binds p65 and is necessary for NF-kB p65 target gene expression, for example, of Survivin (left). Mutant p53 mimics NF-kB activation, which constitutively induces expression of anti-apoptotic NF-kB target genes (right).
Control of activated NF-jB by p53 G Schneider et al pro-apoptotic functions of NF-kB (Ryan et al., 2000; Karl et al., 2009 ) and p53/NF-kB-induced pro-apoptotic signaling, for example, by the Fas/FasL system for immunological tumor surveillance (O'Brien et al., 2005) . Such indirect p53-dependent anti-tumor effects would be antagonized when tumors block p53 functions of normal tissue. Indeed, p53 null lung cancer cells secrete factors suppressing p53 in adjacent stromal cells (Bar et al., 2009) .
The dependence of TNF-a-induced NF-kB activation on p53 shows a previously unknown control function for p53 in cytokine signaling. Similar as in replicational stress, linking p53 to NF-kB signaling allows antiapoptotic gene expression in cells where the tumor suppressor can execute apoptosis if necessary. Such situations arise, for example, when TNF promotes inflammation-related tumorigenesis by NF-kB activation (Pikarsky et al., 2004; Hayashi et al., 2007) or by TNF-mediated induction of reactive oxygen species bearing mutagenic potential (Yan et al., 2006; Li et al., 2007; Yazdanpanah et al., 2009) . Of note, p53-positive cells can protect themselves from such cyto-and genotoxic molecules by inducing MnSOD, an antioxidizing enzyme known to balance TNF signaling (Gilmore and Herscovitch, 2006) .
Other NF-kB activating stimuli might equally require p53 for full NF-kB activation. For example, it has been shown that p53 crucially contributes to NF-kB induction in response to the bacterial endotoxin lipopolysaccharide (Scha¨fer et al., 2003) . In contrast, double-strand DNA break inducers cause apoptosis dependent on NF-kB but independent of p53 (Karl et al., 2009) . Hence, the interplay between p53 and NF-kB we describe here is activated by particular stimuli. Thus, cross talk between these transcription factors represents a molecularly defined therapeutic target.
Therefore, modulators of NF-kB, p53 and their associated regulators could be therapeutically useful for the treatment of cancer and inflammation (Gilmore and Herscovitch, 2006; Wang and El-Deiry, 2008; Spange et al., 2009) . Valid targets could equally be the candidate kinase(s) modulating physical and functional interactions between p53 and NF-kB. For example, checkpoint pathways involving ATM, ATR and p38 MAPK are operational on DNA damage and replicational stress (Reinhardt et al., 2007; Grallert and Boye, 2008) . Although we could not detect a lack of ATM or CHK1 activation in HU-treated HCT-116 p53À cells, these kinases could regulate p53-dependent NF-kB actions, possibly collateral with RSK1 and MEK1 that govern the nuclear p53/p65 cross talk (Armstrong et al., 1995; Ryan et al., 2000; Bohuslav et al., 2004; Yoshida et al., 2008) . Our data and a recent report (Kawauchi et al., 2008a) reveal physical interactions between p65 and p53, which may allow an IkB kinase a-dependent transit of CBP (Huang et al., 2007) . The fact that p53 binding to a region in the N-terminal part of p65 does not disrupt IkB kinase a binding to the C-terminal transactivation domain is furthermore compatible with a transcriptionally active p53/p65 complex (Kawauchi et al., 2008a) . Future studies will clarify the exact composition of this protein assembly likely comprising additional proteins. Strikingly, TNF-induced p53 binding to kB consensus DNA peaks before p65 recruitment. Perhaps, this complex is required for opening of chromatin at NFkB loci and for the persistence of p65 at such sites. TP53 might equally replace NF-kB members in this complex and other p53 family members could be involved (Alsafadi et al., 2009) . Furthermore, corepressor/coactivator binding to transcription factors changes in response to physiological and pharmacological stimulation (Kra¨mer, 2009) , any putative interaction partner might exert hub functions (Tsai et al., 2009 ) and the p53 N-terminal transcriptional activation domain is a multifunctional module for dynamic interactions (Kaustov et al., 2006) .
In agreement with such complex regulation of NF-kB and p53 at several steps, these transcription factors can functionally antagonize, cooperate or exhibit independence (Scian et al., 2005; Schumm et al., 2006; Huang et al., 2007; Weisz et al., 2007; Nesic et al., 2008; Szoltysek et al., 2008) . Whereas uninduced wild-type p53 attenuates NF-kB signaling directly or indirectly (Webster and Perkins, 1999; Hoffman et al., 2002; Perkins, 2007; Kawauchi et al., 2008a, b) , p53 regulates NF-kB positively under conditions of cellular stress (Ryan et al., 2000; Bohuslav et al., 2004; Armstrong et al., 2006) . Our analyses elucidate that the p53 hotspot mutant p53 R172H promotes anti-apoptotic activities of NF-kB p65. Weisz et al. (2007) accordingly showed that p53 R175H corresponding to murine p53 R172H prolongs nuclear localization and activity of induced NF-kB p65. Moreover, expression of mutated p53 positively correlates with nuclear p65 expression in head and neck squamous cell carcinomas and non-small cell lung cancers (Weisz et al., 2007) .
Mutant p53 cannot induce pro-apoptotic gene expression but allows productive NF-kB signaling linked to tumor progression, survival and therapeutic resistance. Hence, our observations provide an explanation for the important question why p53 mutations rather than p53 deletions arise in tumors (Deppert, 2007; Soussi and Wiman, 2007) . Consistent with this, it was found that chemotherapeutics, hypoxia and oncogene activation induce checkpoint activation, replicational arrest and selection for aberrant p53 (Hanahan and Weinberg, 2000; Janssens and Tschopp, 2006; Finkel et al., 2007; Marusyk and DeGregori, 2007; Kra¨mer, 2009; Viale et al., 2009 ).
Materials and methods
These are described in Supplementary Materials and Methods and in recent publications (Schneider et al., 2006; Knauer et al., 2007; Seidler et al., 2008; Fritsche et al., 2009; Kra¨mer et al., 2009) .
